neurology

News in brief: Aubagio to be PBS delisted for MS patients; Risdiplam benefits seen in infants with type 1 SMA; Late-onset epilepsy link to mortality;

Aubagio brand of ​teriflunomide to be PBS delisted People with MS have been advised that the Aubagio brand of ​teriflunomide disease modifying therapy (DMT) marketed by  Sanofi will be delisted from the PBS in October 2021. According to MS Australia, the availability of seven other generic brands of teriflunomide following the expiry of the patent ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic